Oramed Pharmaceuticals’ (NASDAQ, TASE:ORMP) majority-owned subsidiary, Oravax Medical, received clearance from the South African Health Products Regulatory Authority to begin patient enrollment in a first-in...
Radiopharmaceuticals developer, POINT Biopharma Global (NASDAQ:PNT), and Kinectrics entered into a long-term supply agreement for Ytterbium-176 (Yb-176) to support POINT’s in-house no-carrier added Lutetium-177 (n.c.a...
Kezar Life Sciences (NASDAQ:KZR) dosed the first patient in a Phase 1 clinical trial evaluating KZR-261, a broad-spectrum, anti-tumor agent that acts through direct interaction and inhibition of the Sec61 translocon...
Altamira Therapeutics (NASDAQ:CYTO) signed a letter of understanding (LOU) with Singapore’s Wellesta Holdings for the marketing and distribution of Bentrio, its nasal spray for protection against airborne viruses and...
111, Inc. (NASDAQ:YI) entered into a strategic cooperation agreement with Chugai Pharma China. The agreement would allow the two companies to build a “Healthy China” by establishing a “SMART Healthcare...
Titan Pharmaceuticals (NASDAQ:TTNP) has received funding from the Bill & Melinda Gates Foundation to support its ability to deliver a human immunodeficiency virus (HIV) preventative therapeutic and a contraceptive...
Closely-held PharmaJet’s Tropis intradermal needle-free injection system is being used in a campaign in Somalia, delivering inactivated polio vaccine to more than 110,000 children. The purpose of the campaign, funded in...
The Hash Corporation (CSE:REZN) launched its suite of specialty hash products – Gold Seal Hash and Cold Tumbled Resin – to licensed retailers via the Ontario Cannabis Store. Both products are manufactured by a...
Sio Gene Therapies (NASDAQ:SIOX) presented positive interim data from its ongoing Phase 1/2 study of AXO-AAV-GM1, its adeno-associated viral vector 9-based gene therapy candidate for the treatment of GM1 gangliosidosis...
The FDA approved Cognetivity Neurosciences’ (CSE:CGN; OTCQB:CGNSF; FWB:1UB) 510(k) submission of its Integrated Cognitive Assessment (ICA) as a Class 2 exempt medical device, clearing the way for a commercial rollout...